BRIEF published on 12/22/2025 at 07:05, 1 month 14 days ago GenSight Biologics Receives Compassionate Use Authorization for GS010/LUMEVOQ® in France Gene Therapy Rare Diseases Compassionate Use LHON Treatment ANSM Approval
PRESS RELEASE published on 12/22/2025 at 07:00, 1 month 14 days ago Informations privilégiées / Autres communiqués GenSight Biologics obtient une autorisation d'accès compassionnel en France pour GS010/LUMEVOQ dans le traitement de la NOHL liée à la mutation ND4 Thérapie Génique GenSight Biologics NOHL GS010/LUMEVOQ Autorisation D'accès Compassionnel
PRESS RELEASE published on 12/22/2025 at 07:00, 1 month 14 days ago Inside Information / Other news releases GenSight Biologics receives Compassionate Use Authorization in France for GS010/LUMEVOQ® gene therapy indicated for ND4-LHON treatment France GenSight Biologics GS010/LUMEVOQ® Compassionate Use Authorization ND4-LHON
BRIEF published on 11/13/2025 at 18:02, 2 months 22 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 11/13/2025 at 18:02, 2 months 22 days ago Franchissement de seuils par Heights Capital Management Obligations Convertibles Franchissement De Seuils GenSight Biologics Actions Et Droits De Vote Heights Capital
PRESS RELEASE published on 11/13/2025 at 17:57, 2 months 22 days ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management pour le compte de CVI Investments, Inc. concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Franchissement De Seuils GENSIGHT BIOLOGICS SA Heights Capital Management CVI Investments Inc.
BRIEF published on 10/30/2025 at 07:35, 3 months 6 days ago GenSight Biologics : Feu vert pour un traitement compassionnel aux États-Unis FDA GenSight Biologics NOHL Accès Compassionnel GS010/LUMEVOQ®
BRIEF published on 10/30/2025 at 07:35, 3 months 6 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
PRESS RELEASE published on 10/30/2025 at 07:30, 3 months 6 days ago Informations privilégiées / Autres communiqués GenSight Biologics a obtenu les autorisations réglementaires pour un traitement compassionnel aux États-Unis avec GS010/LUMEVOQ, visant la Neuropathie Optique Héréditaire de Leber FDA GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ Traitement Compassionnel
BRIEF published on 09/29/2025 at 23:05, 4 months 6 days ago GenSight Biologics annonce ses résultats financiers du premier semestre 2025 Résultats Financiers Recherche Et Développement Trésorerie GenSight Biologics Programmes D'accès Précoce
Published on 02/06/2026 at 00:00, 7 minutes ago LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Published on 02/05/2026 at 23:00, 1 hour 7 minutes ago Grounded People Announces Non-Brokered Private Placement and Strategic Review
Published on 02/05/2026 at 21:00, 3 hours 7 minutes ago Kidoz Welcomes CloudX Innovation Driving Fairer Mobile Advertising Auctions
Published on 02/05/2026 at 18:50, 5 hours 17 minutes ago Athena Gold Provides Exploration Update From Nevada and Ontario
Published on 02/05/2026 at 19:27, 4 hours 39 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/05/2026 at 18:46, 5 hours 21 minutes ago EQS-Adhoc: Mayr-Melnhof Karton AG: Impairment requirements impact profit for the financial year 2025
Published on 02/05/2026 at 18:09, 5 hours 58 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/05/2026 at 17:55, 6 hours 12 minutes ago Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Published on 02/05/2026 at 17:40, 6 hours 27 minutes ago BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.02.26.
Published on 02/05/2026 at 19:15, 4 hours 52 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 4 hours 52 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026
Published on 02/05/2026 at 19:15, 4 hours 52 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
